Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Christine Marie Utter net worth and biography

Christine Utter Biography and Net Worth

CAO of PTC Therapeutics

Since joining PTC in 2010 as the assistant controller, Christine Utter has consistently taken on new responsibilities, growing to become senior vice president of finance and chief accounting officer in 2017. Previously, she was the assistant corporate controller of Barrier Therapeutics and a financial analyst at Engelhard Corporation. Christine holds a B.S. in accounting from the College of New Jersey and is a certified public accountant.

What is Christine Marie Utter's net worth?: The estimated net worth of Christine Marie Utter is at least $2.42 million as of December 2nd, 2024. Ms. Utter owns 52,428 shares of PTC Therapeutics stock worth more than $2,424,271 as of December 21st. This net worth evaluation does not reflect any other assets that Ms. Utter may own. Additionally, Ms. Utter receives an annual salary of $595,540.00 as CAO at PTC Therapeutics. Learn More about Christine Marie Utter's net worth.
How old is Christine Marie Utter?: Ms. Utter is currently 46 years old. There are 7 older executives and no younger executives at PTC Therapeutics. The oldest executive at PTC Therapeutics is Dr. Allan Steven Jacobson Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director, who is 78 years old. Learn More on Christine Marie Utter's age.
What is Christine Marie Utter's salary?: As the CAO of PTC Therapeutics, Inc., Ms. Utter earns $595,540.00 per year. There are 5 executives that earn more than Ms. Utter. The highest earning executive at PTC Therapeutics is Dr. Stuart W. Peltz Ph.D., Co-Founder, Senior Consultant & Member of Scientific Advisory Board, who commands a salary of $1,540,000.00 per year. Learn More on Christine Marie Utter's salary.
How do I contact Christine Marie Utter?: The corporate mailing address for Ms. Utter and other PTC Therapeutics executives is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected]. Learn More on Christine Marie Utter's contact information.
Has Christine Marie Utter been buying or selling shares of PTC Therapeutics?: During the last quarter, Christine Marie Utter has sold $921,506.00 in shares of PTC Therapeutics stock. Most recently, Christine Marie Utter sold 17,800 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $51.77, for a transaction totalling $921,506.00. Following the completion of the sale, the chief accounting officer now directly owns 52,428 shares of the company's stock, valued at $2,714,197.56. Learn More on Christine Marie Utter's trading history.
Who are PTC Therapeutics' active insiders?: PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Pierre Gravier (CFO), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Emma Reeve (Director), Michael Schmertzler (Director), David Southwell (Director), Dawn Svoronos (Director), Christine Utter (CAO), Alethia Young (Chief Financial Officer, Bicycle Therapeutics), and Jerome Zeldis (Director). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 253,856 shares worth more than $12,039,652.16. The most recent insider tranaction occured on December, 2nd when insider Neil Gregory Almstead sold 69,550 shares worth more than $3,620,773.00. Insiders at PTC Therapeutics own 5.5% of the company. Learn More about insider trades at PTC Therapeutics.
Information on this page was last updated on 12/2/2024.

Christine Marie Utter Insider Trading History at PTC Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/2/2024	Sell	17,800	$51.77	$921,506.00	52,428
1/30/2024	Sell	318	$27.25	$8,665.50	35,528
1/8/2024	Sell	1,188	$28.64	$34,024.32	37,499
4/21/2023	Sell	4,692	$55.06	$258,341.52	38,059
3/29/2023	Sell	4,688	$47.79	$224,039.52	38,059
3/27/2023	Sell	26,658	$45.09	$1,202,009.22	38,059
1/31/2023	Sell	325	$45.63	$14,829.75	38,059
1/11/2023	Sell	417	$44.36	$18,498.12	38,384
1/9/2023	Sell	706	$41.66	$29,411.96	39,290
2/1/2022	Sell	313	$40.00	$12,520.00
1/18/2022	Sell	11,428	$43.94	$502,146.32
1/7/2022	Sell	747	$38.52	$28,774.44
2/1/2021	Sell	368	$56.96	$20,961.28	17,161
2/1/2021	Sell	368	$56.96	$20,961.28	17,161
1/5/2021	Sell	316	$62.37	$19,708.92
11/4/2020	Sell	31,758	$60.06	$1,907,385.48	11,129
10/6/2020	Sell	2,500	$50.08	$125,200.00	10,349
7/6/2020	Sell	3,288	$53.70	$176,565.60
4/17/2020	Sell	2,145	$50.00	$107,250.00	11,449
4/3/2020	Sell	787	$44.31	$34,871.97	10,091
1/7/2020	Sell	13,750	$50.02	$687,775.00	5,224
7/1/2019	Sell	14,059	$45.14	$634,623.26	5,173
6/28/2019	Sell	988	$45.00	$44,460.00	5,173
3/5/2019	Sell	28,709	$34.97	$1,003,953.73	5,937
1/7/2019	Sell	297	$34.75	$10,320.75
1/4/2018	Sell	412	$17.67	$7,280.04

Christine Marie Utter Buying and Selling Activity at PTC Therapeutics

PTC Therapeutics Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $46.24

$44.74

$47.42

50 Day Range

MA: $43.50

$36.70

$52.07

2 Week Range

Now: $46.24

$23.58

$54.16

Volume

1,431,601 shs

Average Volume

849,432 shs

Market Capitalization

$3.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

AI breakthrough about to upend industry

From Porter & Company | Ad

Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

I urge you to watch it now.

Christine Utter Biography and Net Worth

What is Christine Marie Utter's net worth?

How old is Christine Marie Utter?

What is Christine Marie Utter's salary?

How do I contact Christine Marie Utter?

Has Christine Marie Utter been buying or selling shares of PTC Therapeutics?

Who are PTC Therapeutics' active insiders?

Are insiders buying or selling shares of PTC Therapeutics?